The Polygon team announced plans to increase the gas limit, expanding the size of each block. Polygon aimed for a higher capacity, due to demand for stablecoin transfers.The Polygon team announced plans to increase the gas limit, expanding the size of each block. Polygon aimed for a higher capacity, due to demand for stablecoin transfers.

Polygon schedules network upgrade to support growing demand for stablecoins

2025/09/16 22:21
3 min read

Polygon developers plan to increase transaction capacity by 33% in the coming months to tap into increased demand for stablecoin usage. Polygon is one of the legacy L2 chains to see a significant surge in 2025 traffic. 

Polygon developers have announced plans to increase the network transaction capacity by 33% in the last quarter of 2025. Polygon is a legacy network that has carried multiple Web3 apps, games, and DeFi platforms. 

Based on a recent proposal, Polygon will allow more transactions in each block, boosting overall capacity. The protocol change will affect all validators and will not require additional coordination or consensus. 

The increased block size may lead to challenges with block propagation, as reflected in the proposal. This is not a new occurrence with Polygon, which recently had an outage, as Cryptopolitan reported

Polygon tapped growing activity during the 2025 bull market

Polygon noted increased gas usage in 2025, reflecting its central role in prediction markets and general stablecoin transfers. 

Polygon aims to increase transaction capacity on growing demand for stablecoinsPolygon activity picked up in 2025, leading to the proposal for increasing the gas limit, allowing more transactions in each block. | Source: Polygonscan

To boost usage, the Polygon team aims to increase throughput by 33% by increasing the maximum gas limit. Polygon has already shown a jump in transactions in 2025, coinciding with the recent bull market. 

Currently, Polygon is still a highly accessible network, with transactions costing under $0.01. Even during periods of congestion, transactions only reach $0.10 at the highest. As of September 16, the Origin:Turbine smart contract is the busiest, followed by the QuickSwap V2 router. 

In the past six months, Polygon transactions have increased gradually, as L2 chains drew in more activity. Around 13.6% of the Ethereum ecosystem activity happens on L2 chains. 

Polygon gets a boost from active stablecoin transfers

Polygon is among the top networks for stablecoin transfers. The chain only carries around $2.9B in total stablecoin supply, based on native or bridged tokens

Despite this, Polygon is among the top chains for USDT, USDC, and USDS transfers, based on Dune Analytics data. The chain is closely linked to the Ethereum ecosystem and has been used for DeFi and gaming in previous bull markets. 

USDC is one of the most widely used tokens, tied to activity on Polymarket. QuickSwap is also driving activity, as the most active native DEX on the chain. The chain also carries one of the still-active on-chain games, Sunflower Land, which also uses USDC for in-game items. 

Polygon was seen as one of the more reliable chains, with the ability to challenge Ethereum. The expansion of L2 chains displaced the network, and briefly, the chain turned into a degen hotspot, an NFT trading chain, and a multi-purpose arena for degen trading and risky projects. 

The newly launched zkEVM version is still growing its user base. In 2025, Polygon aims to reposition itself as one of the reliable chains, serving as a hub for fintech, payments and tokenized assets. 

Polygon’s utility has not been reflected in its native token. In 2025, POL traded near its lower range, sliding to around $0.27 from a peak at $0.60 in late 2024.

KEY Difference Wire: the secret tool crypto projects use to get guaranteed media coverage

Market Opportunity
Blockstreet Logo
Blockstreet Price(BLOCK)
$0.007592
$0.007592$0.007592
-0.14%
USD
Blockstreet (BLOCK) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26